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Latency-associated nuclear antigen 1 (LANA1) binds to Kaposi’s sarcoma-associated herpesvirus (KSHV) terminal repeat (TR) DNA to
mediate episome replication and persistence. LANA1 concentrates at sites of TR DNA along mitotic chromosomes, consistent with tethering
KSHV DNA to chromosomes for efficient segregation of episomes to progeny nuclei. We now investigate LANA1 C-terminus self-
association and DNA binding. The TR DNA binding domain was localized to LANA1 residues 996–1139. Scanning deletions within this
region ablated both LANA1 oligomerization and DNA binding, consistent with a requirement for oligomerization to bind DNA. Furthermore,
LANA1 bound TR DNA as an oligomer. Deletion of amino acids 1007–1021, N-terminal to the LANA1 oligomerization domain, ablated
DNA binding, DNA replication, and episome persistence, implicating these residues in contacting DNA. Indeed, LANA1 residues 1007–
1021 correspond to EBNA1 residues that contact the cognate sequence. Like EBNA1, the LANA1 DNA-binding domain has oligomerization
activity and critical residues essential for recognizing DNA.
D 2004 Elsevier Inc. All rights reserved.Keywords: KSHV LANA1; Episome persistenceIntroduction
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV)
is a gamma-2 herpesvirus tightly linked to KS, primary
effusion lymphoma (PEL), and multicentric Castleman’s
disease (Chang et al., 1994; Moore and Chang, 1995;
Soulier et al., 1995). KSHV infection of tumor cells and
PEL cell lines is predominantly latent. Latently infected
cells contain multiple copies of extrachromosomal, circu-
larized KSHV DNA (episomes) (Cesarman et al., 1995;
Decker et al., 1996). To persist in proliferating cells, KSHV
episomes must replicate and efficiently segregate to progeny
cells.0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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expressed from KSHV open reading frame 73 (Kedes et
al., 1997; Kellam et al., 1997; Rainbow et al., 1997).
LANA1 has a proline-rich N-terminal domain, central acidic
and glutamine-rich repeat elements, a predicted leucine
zipper, and a C-terminal domain (Fig. 1) (Neipel et al.,
1997; Russo et al., 1996). The number of central repeat
elements may vary among KSHV strains, leading to
LANA1 molecules of different sizes (Gao et al., 1999).
Confocal microscopy demonstrates that LANA1 associates
with mitotic chromosomes and concentrates at sites of
KSHV episomes (Ballestas et al., 1999; Cotter and Robert-
son, 1999; Szekely et al., 1998). Further, DNA-containing
KSHV terminal repeat (TR) elements persist as episomes in
uninfected cells expressing LANA1 but not in cells which
lack LANA1 (Ballestas et al., 1999). Therefore, LANA1
acts in trans on KSHV TR DNA to mediate episome
persistence. Consistent with these findings, LANA1 binds
specific TR sequence and mediates replication of TR DNA
containing this sequence (Ballestas and Kaye, 2001; Cotter
Fig. 1. Schematic diagram of KSHV LANA1 and LANA1 mutants.
Numbers indicate LANA1 residues (Russo et al., 1996). Each LANA1
mutant’s ability (+ or  ) to bind TR probe is indicated at the right. P,
proline rich region; LZ, leucine zipper.
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2003; Hu et al., 2002; Lim et al., 2002). The LANA1 C-
terminus binds TR DNA and also mediates LANA1 self-
association (Cotter et al., 2001; Garber et al., 2001; Lim et
al., 2002; Schwam et al., 2000). Taken together, these data
support a model in which LANA1 mediates KSHV TR
DNA replication and then tethers episomes to mitotic
chromosomes to efficiently partition them to progeny nu-
clei. Similar roles in episome persistence have been pro-
posed for the EBV EBNA1 and bovine papillomavirus E2
proteins (Bastien and McBride, 2000; Ilves et al., 1999;
Lehman and Botchan, 1998; Rawlins et al., 1985; Skiado-
poulos and McBride, 1998; Yates et al., 1984, 1985).
The precise nature by which LANA1 binds TR DNA
remains to be elucidated, and this work investigates LANA1
C-terminal self-association and DNA binding. The LANA1
oligomerization domain is found to be critical for DNA
binding. Additional sequence in the LANA1 DNA-binding
domain is also identified that is essential for DNA binding,
DNA replication, and episome maintenance.Results
Localization of the LANA1 TR DNA-binding domain to
residues 996–1139
LANA1 domains were investigated by electrophoresis
mobility shift assay (EMSA) for the ability to bind TR
DNA. In vitro translated F-LANA1 or RBP-Jn was incu-
bated with TR probe, and EMSA was performed. The TR
probe is a 20-base pair KSHV TR sequence to which
LANA1 binds (Ballestas and Kaye, 2001; Cotter et al.,
2001; Garber et al., 2001), while RBP-Jn is a DNA-binding
protein which lacks a cognate sequence in the TR probe(Grossman et al., 1994; Henkel et al., 1994). F-LANA1
formed two complexes (Fig. 2A, lane 1, arrows) (Ballestas
and Kaye, 2001), whereas RBP-Jn did not bind the TR
probe and resulted only in nonspecific gel shifts due to the
reticulocyte lysate (Fig. 2A, lane 2, (NSB)). F-LANA1
496–1162 generated two specific complexes (Fig. 2A, lane
3, asterisks) and incubation with 50-fold excess non-radio-
labeled TR DNA competed these shifts (Fig. 2A, lane 4).
EMSA with F-LANA1 275–777 and F-LANA1 5–465 did
not generate specific complexes (Fig. 2A, lanes 5–8). These
results demonstrate that F-LANA1 496–1162, which con-
tains LANA1 repeat elements, the predicted leucine zipper
and C-terminus (Fig. 1), specifically bound the TR probe
whereas LANA1 N-terminal (5–465) and central repeat
regions (275–777) did not.
Because both F-LANA1 496–1162 and F-LANA1 275–
777 contain repeat elements but only F-LANA1 496–1162
bound the TR probe, these data indicate that the DNA-
binding domain is composed of the leucine zipper or the
downstream C-terminal sequence. F-LANA1 779–1162,
which lacks most of the LANA1 repeat elements but
contains the leucine zipper and C-terminus (Fig. 1), bound
the TR probe in specific complexes (Fig. 2B, lane 5,
asterisks). Incubation of excess non-radiolabeled TR DNA
competed the shifts (Fig. 2B, lane 7) but excess unlabeled,
mutated TR DNA, which differs from TR probe by two
nucleotides and does not efficiently compete LANA1 com-
plexes (in preparation), did not significantly compete the
gel-shifted complexes (Fig. 2B, lane 6). F-LANA1 981–
1162, which lacks the leucine zipper (Fig. 1), also specif-
ically bound TR DNA (Fig. 2C, lane 10, adjacent line). The
F-LANA1 981–1162 complexes were not sharply defined,
consistent with results in which an even larger LANA1 C-
terminal region (951–1162) formed a broad, indistinct
complex with TR probe (Lim et al., 2002). Excess non-
radiolabeled TR DNA (Fig. 2C, lane 11) competed the F-
LANA1 981–1162 complexes. F-LANA1 779–1049 did
not form specific gel shifts (Fig. 2B, lanes 1–3), similar to
RBP-Jn (Fig. 2B, lane 4). These results demonstrate that the
LANA1 C-terminal 182 amino acids present in LANA1
981–1162 are sufficient for TR DNA binding. In addition,
LANA1 residues C-terminal to 1049 are required for gel
shift activity, whereas the predicted LANA1 leucine zipper
is not.
Supershift analyses confirmed the presence of the
LANA1 C-terminus in the gel-shifted complexes. F-LANA1
complexes (Fig. 2C, lane 1, arrows) were supershifted by
M2 (anti-FLAG) antibody (Fig. 2C, lane 3), but not by
isotype control antibody (Fig. 2C, lane 4), and were com-
peted with excess, non-radiolabeled TR DNA (Fig. 2C, lane
2). Similarly, F-LANA1 779–1162 complexes (Fig. 2C,
lane 6, asterisks) were supershifted to the gel origin (O)
(Fig. 2C, lane 8) by anti-LANA1 antibody (LR) which
recognizes a LANA1 repeat element (Kellam et al., 1999),
but not by control antibody (Fig. 2C, lane 9). Excess,
unlabeled TR DNA competed the F-LANA1 779–1162
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rather than M2 (anti-FLAG), was used to supershift F-
LANA1 779–1162 because M2 repeatedly failed to super-
shift these complexes (data not shown), likely due to
inaccessibility of the FLAG epitope in F-LANA1 779–
1162 bound to DNA. F-LANA1 981–1162 complexes (Fig.
2C, lane 10, indicated by adjacent line) were supershifted
(Fig. 2C, lane 12, circles) into discrete complexes by M2 but
not the control (Fig. 2C, lane 13) antibody. The M2-super-
shifted F-LANA1 981–1162 complexes were more intense
than the non-supershifted complexes, consistent with the
possibility that the M2 antibody enhanced probe binding.Therefore, LANA1 C-terminal domains are present in the
specific gel-shifted complexes.
Because the EMSA assays used in vitro translated
protein, LANA1 proteins expressed in vivo were also
assayed for the ability to bind TR DNA. F-LANA1, F-
LANA1 981–1162, F-LANA1 779–1162, and F-LANA1
779–1049 were each expressed in uninfected BJAB B
lymphoma cells (Menezes et al., 1975). Cell lysates were
immunoprecipitated with M2 anti-FLAG antibody or iso-
type control antibody and incubated with TR probe. Bound
TR probe was eluted from the immune precipitates and
resolved on a polyacrylamide gel. After immune precipita-
tion with M2, F-LANA1 (Fig. 2D, lane 1), F-LANA1 779–
1162 (Fig. 2D, lane 5), and F-LANA1 981–1162 (Fig. 2D,
lane 3) bound the probe. The binding was specific because
immune precipitates of F-LANA1 (Fig. 2D, lane 2), F-
LANA1 779–1162 (Fig. 2D, lane 6), and F-LANA1 981–
1162 (Fig. 2D, lane 4) with isotype control antibody (C) did
not bind the probe. F-LANA1 779–1049 did not bind the
probe after immune precipitation with M2 (Fig. 2D, lane 7).
Therefore, these binding assays were consistent with the
EMSA results.
Bacterially expressed LANA1 was used to assay whether
the LANA1 C-terminus directly binds TR DNA in the
absence of mammalian cell proteins. GST and GST LANA1
982–1162 were assayed for TR binding. GST LANA1
982–1162 (Fig. 2E, lane 2) but not GST (Fig. 2E, lane 1)
bound the probe. This result indicates a direct interaction
between LANA1 and TR DNA.
EMSA experiments further localized the C-terminus of
the LANA1 DNA binding domain. F-LANA1 (Fig. 3A, lane
1, arrows) complexes were competed with excess unlabeledFig. 2. The LANA1 C-terminus binds KSHV TR DNA. (A) EMSA with
F-LANA1, LANA1 mutants, and RBP-Jn. Lane 1, F-LANA1; lane 2,
RBP-Jn lanes 3 and 4, F-LANA1 496–1162; lanes 5 and 6, F-LANA1
275–777; lanes 7 and 8, F-LANA1 5–465. Fifty-fold excess, non-
radiolabeled TR oligonucleotide was added to the incubation in lanes 4, 6,
and 8. Asterisks indicate F-LANA1 496–1162 and arrows indicate F-
LANA1 complexes. (B) EMSA with F-LANA1 779–1049 (lanes 1–3),
RBP-Jn (lane 4), and F-LANA1 779–1162 (lanes 5–7). Fifty-fold excess
unlabeled TR oligonucleotide (lanes 3 and 7) or mutated TR
oligonucleotide (M, lanes 2 and 6) was added to the incubation. Asterisks
indicate F-LANA1 779–1162 complexes. (C) EMSA with F-LANA
(lanes 1–4), RBP-Jn (lane 5), F-LANA1 779–1162 (lanes 6–9), and F-
LANA1 981–1162 (lanes 10–13). Fifty-fold excess, non-radiolabeled TR
oligonucleotide (lanes 2, 7, and 11), M2 anti-FLAG (lanes 3 and 12), anti-
LANA1 repeat (LR) (lane 8), or control (lanes 4, 9, and 13) antibody was
added to the incubation. Asterisks indicate F-LANA1 779–1162 and
vertical line indicates F-LANA1 981–1162 complexes. Circles indicate F-
LANA1 981–1162 supershifted complexes. O, gel origin. (A, B, and C)
Free probe was run off the gels. NSB, nonspecific bands. (D) F-LANA1
(lanes 1 and 2), F-LANA1 981–1162 (lanes 3 and 4), F-LANA1 779–
1162 (lanes 5 and 6), and F-LANA1 779–1049 (lanes 7 and 8) were each
expressed in BJAB cells and immune precipitated with M2 (lanes 1, 3, 5,
and 7) or isotype control (lanes 2, 4, 6, and 8) antibody. Complexes were
incubated with TR probe and bound probe eluted. (E) GST (lane 1) or
GST LANA1 982–1162 (lane 2) was incubated with TR probe and bound
probe eluted off the beads. The data presented are representative of at
least two experiments.
Fig. 3. Localization of the TR DNA-binding domain within the LANA1 C-
terminus. (A) EMSA with F-LANA1 (lanes 1–3), RBP-Jn (lane 4), F-
LANA1 5–1139 (lanes 5 and 6), and F-LANA1 5–1075 (lanes 7 and 8).
Fifty-fold excess, non-radiolabeled TR DNA (lanes 3, 6, and 8) or mutated
TR DNA (lane 2) was added to the incubation. Free probe was run off the
gel to allow resolution of the F-LANA1 complexes. (B) F-LANA1 981–
1162 complexes (lanes 1–6) resolved in a 5% polyacrylamide gel and a
short gel run. Twenty-five (lane 3) or 50-fold (lane 4) excess, non-
radiolabeled TR DNA or 50-fold excess mutated TR DNA (lane 2) was
added to the incubation. M2 (lane 5) or isotype control (lane 6) antibody
was added to the incubation. (C) T7-LANA1 996–1151 (lanes 1–6) or
reticulocyte lysate (lane 7) complexes resolved in a 5% polyacrylamide gel
with a short gel run. Twenty-five (lane 3) or 50 (lane 4)-fold excess,
unlabeled TR DNA or 50-fold excess non-radiolabeled mutated TR DNA
(lane 2) was added to the incubation. T7 (lane 5) or isotype control (lane 6)
antibody was added to the incubation. Vertical line indicates the T7-
LANA1 996–1151 complex. Asterisks indicate T7 supershifted complexes.
Arrows indicate specific gel shifted complexes. O, gel origin; NSB,
nonspecific band.
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DNA (Fig. 3A, lane 2). F-LANA1 5–1139 (Fig. 1) also
formed complexes (Fig. 3A, lane 5) which were competed
with excess unlabeled TR DNA (Fig. 3A, lane 6). In
contrast, F-LANA1 5–1075 (Fig. 1) did not form complex
with the TR probe (Fig. 3A, lane 7). Therefore, the C-
terminus of the minimal LANA1 DNA-binding domain is
between amino acids 1075 and 1139.
Experiments also further defined the N-terminal limit of
the LANA1 DNA-binding domain. Distinct F-LANA1
981–1162 complexes (Fig. 3B, lane 1, arrows) were
detected using a high percentage gel and were competedby excess non-radiolabeled TR DNA (Fig. 3B, lanes 3 and
4) but not excess mutated TR DNA (Fig. 3B, lane 2). F-
LANA1 981–1162 complexes were supershifted with M2
(Fig. 3B, lane 5) but not with the control antibody (Fig. 3B,
lane 6). T7-LANA1 996–1151 (Fig. 1) formed a complex
(Fig. 3C, lane 1, vertical line) which was competed with
excess TR DNA (Fig. 3C, lanes 3 and 4), but not with
excess mutated TR DNA (Fig. 3C, lane 2). The T7-LANA1
996–1151 complexes were supershifted with anti-T7 anti-
body into at least two complexes (Fig. 3C, lane 5, asterisks),
but not with the control antibody (Fig. 3C, lane 6). Non-
specific bands (NSB) were generated by reticulocyte lysate
alone (Fig. 3C, lane 7) and were present in all lanes. These
results indicate that the N-terminal limit of the LANA1
DNA-binding domain extends at least to amino acid 996.
Taken together, these results localize the LANA1 DNA-
binding domain to residues 996–1139.
LANA1 mutants ablated for oligomerization do not bind
DNA
Scanning deletions were generated in the F-LANA1
DNA-binding domain (Fig. 4A) and each mutant assayed
for TR binding by EMSA. F-LANA1 formed complexes
(Fig. 4B, lanes 1 and 10) which were competed with excess
unlabeled TR DNA (Fig. 4B, lane 2). However, F-LANA1
D1007–1021 (Fig. 4B, lane 4), F-LANA1 D1025–1039
(Fig. 4B, lane 6), F-LANA1 D1041–1062 (Fig. 4B, lane
16), F-LANA1 D1063–1076 (Fig. 4B, lane 12), F-LANA1
D1077–1090 (Fig. 4B, lane 14), and F-LANA1 D1091–
1112 (Fig. 4B, lane 8) did not form specific complexes.
Nonspecific complexes detected with RBP-Jn (Fig. 4B,
lanes 3 and 11) were present in all lanes (Fig. 4B, NSB).
Therefore, all deletions, which span LANA1 residues
1007–1112, ablated LANA1’s ability to bind the TR probe.
Expression of each of the LANA mutants was confirmed by
immunoblot (data not shown) so the lack of gel shift activity
was not due to the absence of protein expression.
Because the LANA1 C-terminus mediates LANA1 self-
association (Schwam et al., 2000) in addition to DNA
binding, it is possible that deletions also interfered with
LANA1’s ability to self-associate. Because many DNA-
binding proteins, such as EBV EBNA1 (Chen et al., 1993),
bind DNA as dimers, loss of LANA1 self-association could
potentially interfere with DNA binding. The possibility that
the LANA1mutants affected LANA1’s ability to oligomerize
was investigated with co-immunoprecipitation experiments.
Myc epitope tagged LANA1 was co-expressed with each
deletion mutant in COS cells. Myc-LANA1 coprecipitated F-
LANA1 (Fig. 5, lane 2) and F-LANA1 D1007–1021 (Fig. 5,
lane 4) but did not coprecipitate F-LANA1 D1025–1039
(Fig. 5, lane 6), F-LANA1 D1041–1062 (Fig. 5, lane 12), F-
LANA1 D1063–1076 (Fig. 5, lane 8), F-LANA1 D1077–
1090 (Fig. 5, lane 10), or F-LANA1 D1091–1112 (Fig. 5,
lane 14). FLAG epitope tagged LANA1 proteins (Fig. 5,
lanes 1, 3, 5, 7, 9, 11, and 13) and myc-LANA1 (data not
Fig. 4. Scanning deletions within the LANA1 DNA-binding domain ablate gel shift activity. (A) Schematic diagram of LANA1 deletion mutants. Numbers
indicate LANA1 amino acids. F-LANA1 D1007–1021, F-LANA1 D1025–1039, F-LANA1 D1041–1062, F-LANA1 D1063–1076, F-LANA1 D1077–1090,
and F-LANA1 D1091–1112 are each deleted for the indicated LANA1 residues (Russo et al., 1996). Ability to gel shift TR probe or to co-immunoprecipitate
with myc-LANA1 (see Fig. 5) is indicated at the right for each mutant. (B) EMSA with F-LANA1 (lanes 1, 2, and 10), RBP-Jn (lanes 3 and 11), F-LANA1
D1007–1021 (lanes 4 and 5), F-LANA1 D1025–1039 (lanes 6 and 7), F-LANA1 D1091–1112 (lanes 8 and 9), F-LANA1 D1063–1076 (lane 12 and 13), F-
LANA1 D1077–1090 (lanes 14 and 15), and F-LANA1 D1041–1062 (lanes 16 and 17). Fifty-fold, non-radiolabeled excess TR DNA (lanes 2, 5, 7, 9, 13, 15,
and 17) was added to the incubation. Arrows indicate F-LANA1 gel shifted complexes. NSB, nonspecific band.
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coprecipitation was not due to the absence of protein expres-
sion. The finding that all LANA1 mutants that did not self-
associate also did not bind the TR probe was consistent with
LANA1 dimers or higher-order oligomers complexing TR
DNA. Further, these results are consistent with loss of
oligomerization ablating DNA binding. The finding that F-
LANA1 D1007–1021 retained the ability to associate with
myc-LANA1 (Fig. 5, lane 4) but did not bind TR DNA (Fig.
4, lane 4) suggested that these residues specifically recognize
DNA (see Discussion).
LANA1 binds DNA as an oligomer
EMSA experiments investigated whether LANA1 binds
TR DNA in oligomeric form. LANA1 formed specific
complexes with the TR probe (Fig. 6, lane 1, arrow andarrowhead) which were supershifted with anti-LANA1 (Fig.
6, lane 7) but not control (Fig. 6, lane 8) antibody. F-
LANA1 981–1162 formed specific complexes with the TR
probe (Fig. 6, lane 6, adjacent lines) which were super-
shifted with M2 anti-FLAG antibody (Fig. 6, lane 9).
F-LANA1 981–1162 lacks the epitope recognized by
anti-LANA1 antibody and therefore this antibody did not
supershift F-LANA1 981–1162 complexes (Fig. 6, lane
10). Because a lower percentage gel (compared to that in
Fig. 3) was necessary to resolve the large LANA1 com-
plexes, the F-LANA1 981–1162 complexes migrated less
distinctly, similar to that previously observed with F-
LANA1 981–1162 (Fig. 2C, lane 10) and LANA1 951–
1162 (Lim et al., 2002). Because LANA1 complexes
migrate more slowly than F-LANA1 981–1162 complexes,
we reasoned that hetero-oligomers of LANA1 and F-
LANA1 981–1162 bound to TR DNA would form novel
Fig. 6. LANA1 oligomers bind the TR probe. LANA1 and F-LANA1 981–
1162 were either translated alone or cotranslated in vitro and used for
EMSA. Anti-LANA1 (Kellam et al., 1999), M2 anti-FLAG, or control
antibody was added to incubations as indicated. Anti-LANA1 (LR)
antibody detects LANA1 but not F-LANA 981–1162 because the
recognized epitope is deleted. The arrow and arrowhead indicate LANA1
gel-shifted complexes (lane 1). The triangle, asterisk, and circle indicate
novel gel-shifted complexes (lane 2) generated with cotranslation of
LANA1 and F-LANA1 981–1162. Vertical lines (lanes 2 and 6) indicate F-
LANA1 981–1162 complexes. Free probe was run off the gel. O, gel
origin; NSB, nonspecific band. The data presented are representative of
multiple experiments.
Fig. 5. Scanning deletions within the LANA1 C-terminus ablate
oligomerization. After co-expression in COS cells of myc-LANA1 with
F-LANA1 (lanes 1 and 2), F-LANA1 D1007–1021 (lanes 3 and 4), F-
LANA1 D1025–1039 (lanes 5 and 6), F-LANA1 D1063–1076 (lanes 7
and 8), F-LANA1 D1077–1090 (lanes 9 and 10), F-LANA1 D1041–1062
(lanes 11 and 12), or F-LANA1 D1091–1112 (lanes 13 and 14), immune
precipitation with anti-myc antibody was performed and co-precipitating
LANA1 mutants detected with anti-FLAG antibody. The left lane of each
pair (lanes 1, 3, 5, 7, 9, 11, and 13) contains 10% of input and the right lane
of each pair (lanes 2, 4, 6, 8, 10, 12, and 14) contains immunoprecipitates.
The arrow indicates FLAG epitope-tagged LANA1 and LANA1 mutants.
Size standards (kDa) are indicated at the left.
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were cotranslated and EMSAwas performed. Because equal
amounts of DNA were used to cotranslate F-LANA1 981–
1162 and LANA1, we expected F-LANA1 981–1162 to
translate significantly more efficiently than LANA1 due to
its smaller size. Excess F-LANA1 981–1162 protein should
result in most or nearly all of LANA1 forming hetero-
oligomers with F-LANA1 981–1162. EMSA demonstrated
that hetero-oligomers of LANA1 and F-LANA1 981–1162
formed three complexes with the TR probe (Fig. 6, lane 2,
triangle, asterisk, circle). Excess F-LANA1 981–1162 ho-
mo-oligomers also formed complexes (Fig. 6, lane 2,
adjacent lines) similar to those seen with F-LANA1 981–
1162 translated alone (Fig. 6, lane 6). The presence of F-
LANA1 981–1162 and LANA1 hetero-oligomeric com-
plexes indicates that LANA1 binds DNA as an oligomer.
Supershift analyses further investigated the nature of the
hetero-oligomeric complexes. Anti-LANA1 antibody super-
shifted (Fig. 6, lane 3) all three of the hetero-oligomeric
complexes generated after cotranslation of LANA1 and F-
LANA1 981–1162 (Fig. 6, lane 2, triangle, asterisk, circle),
thereby confirming LANA1’s presence in these three com-
plexes. Anti-FLAG M2 antibody, which recognizes F-
LANA1 981–1162 but not LANA1 (which lacks the FLAG
epitope), also supershifted (Fig. 6, lane 4) all three hetero-
oligomeric complexes, confirming F-LANA1 981–1162’s
presence in these complexes. As expected, anti-FLAG
antibody also supershifted homo-oligomeric F-LANA1
981–1162 complexes (Fig. 6, lane 4). Control antibody
did not supershift any of the hetero-oligomeric complexes
(Fig. 6, lane 5). These results demonstrate that LANA1 and
F-LANA1 981–1162 heterodimers, or higher-order hetero-
oligomers, bind the TR probe. The presence of three LANA1
and F-LANA1 981–1162 hetero-oligomeric complexes(Fig. 6, lane 2, triangle, asterisk, circle) raises the possibility
that each complex contains different orders of LANA1 and
F-LANA1 981–1162 hetero-oligomers bound to the probe.
LANA1 residues 1007-1021 are required for TR DNA
binding and replication
Because LANA1 binds TR DNA and mediates TR DNA
replication (Grundhoff and Ganem, 2003; Hu et al., 2002;
Lim et al., 2002), F-LANA1 D1007–1021, which oligo-
merizes but does not bind TR DNA, was assayed for the
ability to mediate TR DNA replication. If direct LANA1
binding to TR sequence is important for replication, then F-
LANA1 D1007–1021 should be ablated or reduced for the
ability to mediate TR replication. Experiments used Z6-BE
(Ballestas and Kaye, 2001), which contains eight copies of
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DpnI digestion to differentiate replicated from unreplicated
Z6-BE DNA. Z6-BE was purified from Dam methylase
positive Escherichia coli, which methylates adenines at
DpnI sites. DpnI restriction enzyme cleaves methylated sites
but does not cleave these sites when adenine methylation is
lost after Z6-BE replication in mammalian cells, which lack
Dam methylase. Therefore, Z6-BE DNA resistant to DpnI
digestion indicates replication in mammalian cells. Z6-BE
DNAwas cotransfected into BJAB cells with F-LANA1, F-
LANA1 D1007–1021, F-LANA1 1058VI1059!AA, or
pSG5 vector. F-LANA1 1058VI1059!AA has VI (residues
1058–1059) mutated to AA but retains the abilities to
coprecipitate with myc-LANA1 and bind the TR probe
(data not shown). Forty-eight hours after transfection, lowFig. 7. F-LANA1 D1007–1021 does not mediate KSHV DNA replication.
Z6-BE, which contains eight copies of the KSHV TR unit, was
cotransfected into BJAB cells with F-LANA1 D1007–1021 (lane 1), F-
LANA1 1058VI1059!AA (lane 2), F-LANA1 (lane 3), or pSG5 (lane 4)
DNA. Low molecular weight DNA was extracted 48 h posttransfection,
digested with NheI and DpnI, resolved, and detected with TR probe. The
asterisk and arrow indicate NheI-linearized, DpnI-resistant DNA (lanes 2
and 3) which co-migrates with Z6-BE NheI-linearized plasmid (lane 5).
Data are representative of at least two experiments.
Fig. 8. Immunofluorescent detection of F-LANA1 D1007–1021 and F-
LANA1 1058VI1059!AA in BJAB cells. Anti-LANA1 antibody (green)
detected F-LANA1 D1007–1021 (top panels) or F-LANA1 1058VI1059
!AA (bottom panels) in the presence (right panels) or absence (left
panels) of Z6-BE DNA. Propidium idodide (red) detects nuclei. Overlay of
green and red generates yellow signal. Confocal microscopy was performed
with a Zeiss Axioskop, PCM2000 hardware, and C-imaging software
(magnification: 630).molecular weight DNA was extracted and digested with
Nhe1 (which linearizes Z6-BE; Fig. 7, lane 5, arrow) and
DpnI. NheI-linearized and DpnI-resistant Z6-BE DNA was
present after cotransfection with F-LANA1 (Fig. 7, lane 3,
asterisk, arrow) and F-LANA1 1058VI1059!AA (Fig. 7,
lane 2, asterisk, arrow). The bands migrating just below the
uppermost DpnI-resistant band in lanes 2 and 3 are due to
partially replicated Z6-BE. In contrast, only DpnI-digested
Z6-BE fragments were present after cotransfection with F-
LANA1 D1007–1021 (Fig. 7, lane 1) and pSG5 (Fig. 7,
lane 4). Therefore, F-LANA1 D1007–1021 does not medi-
ate Z6-BE DNA replication, consistent with a need for
LANA1 binding to TR DNA to mediate its replication.
LANA1 residues 1007-1021 are essential for mediation of
KSHV episome persistence
F-LANA1 D1007–1021 was assayed for loss of the
ability to mediate KSHV episome persistence. If transient
assays of F-LANA1-mediated TR replication (Fig. 7) accu-
rately reflect a role for LANA1-mediated episome replica-
tion in stable cell lines, then F-LANA1 D1007–1021 should
be incapable of replicating episomes, and KSHV DNA
should rapidly be diluted out and lost from a proliferating
cell culture. Further, if LANA1 TR binding is critical for
LANA1 to tether episomes to chromosomes to efficiently
partition KSHV DNA to progeny nuclei, then F-LANA1
D1007–1021 should also be defective for episome segre-
gation. BJAB cells stably expressing F-LANA1 D1007–
1021 (BJAB/F-LANA1 D1007 – 1021) or F-LANA1
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transfected with Z6-BE DNA and cells selected for G418
resistance conferred by the plasmid vector.
Immune fluorescent microscopy investigated F-LANA1
D1007–1021 and F-LANA1 1058VI1059!AA distribution
in BJAB cells. In the absence of Z6-BE, both F-LANA1
D1007–1021 (Fig. 8, green, upper left) and F-LANA1
1058VI1059!AA (Fig. 8, green, lower left) distributed
throughout the nuclei (red) in a fine, punctate distribution
(overlay of green and red generates yellow). A similar
distribution throughout the nuclei was detected in G418-
resistant, Z6-BE-transfected, BJAB/F-LANA1 D1007–1021
cells (Fig. 8, upper right). In contrast, in G418-resistant, Z6-
BE-transfected, BJAB/F-LANA1 1058VI1059!AA cells, F-Fig. 9. BJAB/F-LANA1 D1007–1021 cells do not mediate episome
persistence. G418-resistant, Z6-BE-transfected, BJAB/F-LANA1 D1007–
1021 and BJAB/F-LANA1 1058VI1059!AA cells were lysed in situ in
wells of Gardella gels, electrophoresis performed, DNA transferred to a
nylon membrane, and KSHV TR DNA detected. Lane 1, KSHV-infected
BC1 PEL cells (Cesarman et al., 1995); lane 2, G418-resistant, Z6-BE-
transfected, LANA1-negative BJAB cells; lanes 3 and 4 have independ-
ently derived, G418-resistant, Z6-BE-transfected BJAB/F-LANA1
D1007–1021 cell lines; lane 5, G418-resistant, Z6-BE-transfected, BJAB/
F-LANA1 1058VI1059!AA cells; lane 6, Z6-BE plasmid DNA. The upper
band in lane 1 is episomal KSHV and the lower band in lane 1 is from
linear, replicating KSHV. The asterisk indicates episomal Z6-BE (lane 5)
and covalently closed circular Z6-BE plasmid (lane 6). The upper band in
lane 6 is from nicked plasmid DNA.LANA1 1058VI1059!AA concentrated to dots (Fig. 8, lower
right). Because LANA1 localizes to episomes containing
KSHV TR DNA in concentrated dots (Ballestas et al., 1999;
Cotter and Robertson, 1999), these results were consistent
with the presence of Z6-BE KSHV episomes in the G418-
resistant BJAB/F-LANA1 1058VI1059!AA but not BJAB/
F-LANA1 D1007–1021 cells.
The presence of Z6-BE episomes in G418-resistant
cells was therefore assayed by Gardella gel analysis. In
Gardella gels, live cells are lysed at the gel origin at the
start of the gel run. Episomes as large as 200 kb migrate
into the gel but chromosomal DNA is unable to migrate
into the gel (Gardella et al., 1984). As expected, KSHV-
infected BC-1 PEL cells had episomal DNA (Fig. 9, lane
1). Consistent with the concentrated dots detected by
confocal microscopy, Z6-BE-transfected, G418-resistant,
BJAB/F-LANA1 1058VI1059!AA cells had episomal
DNA (Fig. 9, lane 5, asterisk) which co-migrated with
covalently closed circular Z6-BE plasmid (Fig. 9, lane 6).
In contrast, two independently derived, G418-resistant, Z6-
BE-transfected cell lines, BJAB/F-LANA1 D1007–1021-1
and -2 (Fig. 9, lanes 3 and 4), lacked episomes. As
expected, G418-resistant, Z6-BE-transfected, LANA1-neg-
ative BJAB cells (Fig. 9, lane 2) also lacked episomes.
Z6-BE DNA is integrated into chromosomes in G418-
resistant BJAB/F-LANA1 D1007–1021 and BJAB cells.
Therefore, BJAB/F-LANA1 D1007–1021 but not BJAB/
F-LANA1 1058VI1059!AA cells were ablated for the
ability to mediate Z6-BE episome persistence.Discussion
These results define the 144 LANA1 residues 996–1139
as a KSHV TR DNA-binding domain. Amino acids N-
terminal to 996 were not necessary for binding because T7-
LANA1 996–1151 bound the TR probe (Fig. 3). Residues
C-terminal to 1139 were dispensable for DNA binding
because F-LANA1 5–1139 bound TR DNA (Fig. 3). This
mapping is consistent with and further narrows previously
described TR DNA-binding domains of 238 (LANA1 925–
1162) (Cotter et al., 2001), 234 (LANA1 929–1162)
(Garber et al., 2001), and 212 (LANA1 951–1162) (Lim
et al., 2002) amino acids. The findings that F-LANA1 5–
1075 did not gel shift the TR probe (Fig. 3A, lane 8) and
that LANA1 1–1068 and 1–1112 do not gel shift (Lim et
al., 2002) TR DNA indicate that the LANA1 DNA-binding
domain’s C-terminal limit is between residues 1112 and
1139. Further, the finding that F-LANA1 996–1151 gel
shifted TR DNA, but that F-LANA1 deleted for residues
1007–1021 does not bind TR DNA (Fig. 3C), indicates that
the LANA1 DNA-binding domain’s N-terminal limit is
between residues 996 and 1021.
This work demonstrates that LANA1 binds TR DNA as
an oligomer. First, F-LANA1 981–1162 coexpressed with
LANA1 formed novel complexes with TR DNA (Fig. 6).
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body directed at either F-LANA1 981–1162 or LANA1,
demonstrating that both of these proteins were in the
complexes. Second, LANA1 deletion mutants that could
not oligomerize did not gel shift TR DNA (Fig. 4),
consistent with a requirement for LANA1 oligomerization
to bind DNA. It is possible that the multiple complexes
generated by full-length LANA1 or C-terminal LANA1-
binding domains (Figs. 2–4, 6) (Ballestas and Kaye, 2001;
Cotter et al., 2001; Garber et al., 2001; Lim et al., 2002)
are due to different orders of LANA1 oligomers bound to
TR DNA. LANA1 gel shifts can be resolved into at least
three different complexes on long gel runs (Ballestas and
Kaye, 2001). Many DNA-binding proteins self-associate to
bind DNA. In fact, the EBV EBNA1 protein must dimer-
ize to bind DNA (Chen et al., 1993). It is possible that
LANA1’s focal concentration to dots at sites of KSHV
episomes as detected by confocal microscopy (Ballestas et
al., 1999) may result from a high order of LANA1
multimerization.
It is conceivable that LANA1 oligo- or multimeriza-
tion provides functions similar to those of EBNA1-link-
ing domains (Frappier and O’Donnell, 1991; Su et al.,
1991). EBNA1 C-terminal dimers bind cognate sequence
but gly–arg-rich sequences N-terminal to the DNA-bind-
ing domain mediate higher-order interactions of DNA-
bound EBNA1, resulting in linking of EBNA1-bound
DNA sequences that are at a distance from each other
(Goldsmith et al., 1993; Laine and Frappier, 1995;
Mackey and Sugden, 1997; Su et al., 1991). Linking is
not necessary for DNA binding or EBNA1-mediated
DNA replication but is critical for EBNA1-mediated
episome persistence, consistent with a role in episome
segregation (Avolio-Hunter and Frappier, 1998; Shire et
al., 1999). It is possible that the LANA1 C-terminus
differs from the EBNA1 C-terminus and mediates both
DNA binding and higher-order associations among
LANA1 molecules. Such a capability would raise the
possibility that the approximately 40 KSHV TR’s in a
virus episome are linked among LANA1-binding sites
and that such linking may be important for episome
persistence.
Interestingly, the predicted secondary structure of the
LANA1 C-terminus is highly homologous to that of the
EBNA1 C-terminus (Fischer et al., 1999; Grundhoff and
Ganem, 2003; Kelley et al., 2000). EBNA1 is a 641-amino
acid protein and the structure of dimerized EBNA1 residues
459–607 bound to cognate DNA has been solved. The
EBNA1 dimer is composed of two distinct domains, a core
domain and a flanking domain. The core domain of each
EBNA1 monomer contains the dimerization surface and the
flanking domain makes all DNA sequence-specific contacts
(Bochkarev et al., 1995, 1996). Of note, F-LANA1 D 1041–
1062, F-LANA1 D 1063–1076, F-LANA1 D 1077–1090,
and F-LANA1 D1091–1112 each have deletions within the
predicted LANA1 core–dimerization domain, consistentwith their loss of the ability to coprecipitate with myc-
LANA1 (Fig. 5). Interestingly, F-LANA1 D 1025–1039,
which also lacks the ability to coprecipitate with myc-
LANA1, is deleted for residues within the predicted flank-
ing domain, which does not have a role in EBNA1 dimer-
ization (Bochkarev et al., 1995, 1996; Chen et al., 1993).
F-LANA1 D 1007–1021 is deleted for the sequence pre-
dicted to correspond to an extended EBNA1 chain which
makes EBNA1-specific DNA contacts. Consistent with the
predicted structural homology to EBNA1, LANA1 D 1007–
1021 did not bind TR DNA yet retained the ability to
coprecipitate with myc-LANA1. Based on these similarities,
it is likely that LANA1 1007–1021 residues contact DNA
and are important for sequence-specific binding.
F-LANA1 D1007–1021’s inability to mediate Z6-BE
episome persistence is consistent with a model in which
LANA1 must directly contact DNA to mediate both TR
DNA replication and efficient partitioning of episomes to
progeny cells. It is possible that LANA1 has a similar
function to EBNA1 (Chaudhuri et al., 2001; Dhar et al.,
2001; Gahn and Schildkraut, 1989; Schepers et al., 2001) in
serving as an origin-binding protein and in fact LANA1
associates with ORCs (Lim et al., 2002). Adjacent EBNA1
dimers distort cognate DNA (Bochkarev et al., 1996;
Frappier and O’Donnell, 1992; Harrison et al., 1994; Hear-
ing et al., 1992; Hsieh et al., 1993), similar to other origin-
binding proteins. LANA1 binds to two adjacent sites within
the KSHV TR (Garber et al., 2002), and such binding may
also distort DNA in the process of pre-replication complex
formation. In such a model, loss of the ability to bind the TR
sequence would result in loss of TR replication. F-LANA1
D1007–1021’s inability to bind TR DNA would also ablate
episome partitioning function in the setting of LANA1
directly tethering TR DNA to chromosomes. Future work
should further elucidate the processes by which LANA1
mediates replication and efficient segregation of KSHV
DNA.Materials and methods
Plasmids
pcDNA3 myc-LANA1 contains LANA1 codons 5–1162
cloned downstream of three iterated copies of a myc epitope
in a derivative of pcDNA3 (Aster et al., 1997). F-LANA1
5–465 contains LANA1 codons 5–465 and was con-
structed by cloning the LANA1 SmaI–PstI fragment down-
stream of the FLAG epitope (DYKDDDDK) in pSG5
(Stratagene). F-LANA1 496–1162 contains LANA1 codons
496–1162 from the LANA1 PstI–BamHI fragment inserted
downstream of the FLAG epitope in pSG5-FLAG (Hatzi-
vassiliou et al., 1997). F-LANA1 275–777 and F-LANA1
779–1049 were cloned from LANA1 DpnI fragments, and
F-LANA1 981–1162 was cloned using the LANA1 NruI
site downstream of the FLAG epitope in pSG5. F-LANA1
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F-LANA1 779–1162 each have the indicated LANA1
codons cloned downstream of a FLAG epitope in pSG5.
To generate F-LANA1 5–1075, the PCR product after
amplification of LANA1 DNA with oligonucleotides
ATCTCGCGAATACCGCTATGTACTCAG and AGCA-
GATCTTTAGAAGGCCTGAGATAA was digested and
inserted into the NruI and BglII sites of pSG5 F-LANA1
(Ballestas et al., 1999) in place of the native sequence. For
F-LANA1 5–1139, the PCR product generated after ampli-
fication of LANA1 DNA with oligonucleotides ATC-
TCGCGAATACCGCTATGTACTCAG and AGCA-
GATCTTTAAAACTTAACTATGGA was digested and
inserted into the NruI and BglII sites of pSG5 F-LANA1
(Ballestas et al., 1999) in place of native sequence.
F-LANA1 D1007–1021, F-LANA1 D1025–1039, F-
LANA1 D1041–1062, F-LANA1 D1063–1076, F-LANA1
1077–1090, and F-LANA1 D1091–1112 each are deleted
for the indicated LANA1 codons and F-LANA1
1058VI1059!AA has residues 1058–1959 mutated from
VI to AA. These mutants were cloned by PCR mutagenesis
into pSG5 F-LANA1. pT7N was generated by inserting an
oligonucleotide containing bacteriophage T7 promoter and
T7 epitope sequence into the NheI/BspEI sites of a deriva-
tive of pEGFPc1 (Clontech) containing the EBNA1 NLS
(Hung et al., 2001), resulting in deletion of the enhanced
green fluorescent protein gene but not the NLS. The T7
oligonucleotide was generated by annealing CTAGCTAA-
TACGACTCACTATAGGGAGACCACCATGGCATC-
GATGACAGGTGGCCAACAGATGGGTT wi t h
CCGGAACCCATCTGTTGGCCACCTGTCATCGATGC-
CATGGTGGTCTCCCTATAGTGAGTCGTATTAG. T7N
LANA1 996–1151 was constructed by inserting the appro-
priate LANA1 BstXI restriction fragment downstream of the
T7 epitope in pT7N. GST LANA1 982–1162 contains these
LANA1 codons inserted downstream of GST in pGEX-2TK
(Amersham). Clones were verified by sequencing.
Electrophoresis mobility shift assays (EMSA)
EMSAs were performed as previously described (Balles-
tas and Kaye, 2001). Mutated TR (TR18) (TCCTTCCC-
GGGCATGGGGCC) differs from TR probe (TR13)
(TCCCGCCCGGGCATGGGGCC) (Ballestas and Kaye,
2001) because CG (nucleotides 4 and 5) are mutated to
TT. Briefly, proteins were in vitro translated using the TNT-
coupled reticulocyte lysate systems (Promega) and incubat-
ed with 50000 cpm TR probe. Cotranslation was performed
using 1 Ag of each plasmid DNA in a standard reaction
mixture. Bound and unbound probes were resolved by
electrophoresis in 3.5% or 5% non-denaturing polyacryl-
amide gels in 1 TBE. For supershift assays, monoclonal
antibodies anti-FLAG epitope M2 (Sigma), anti-LANA1
(ABI), anti-T7 epitope (Novagen), or isotype-matched con-
trol antibody (So. Biotechnology Assoc.) was added to the
incubation for 15 min before the addition of radiolabeledprobe. Expression of in vitro translated products was con-
firmed by immunoblot. All EMSAs were performed at least
twice.
DNA binding assays
LANA1 proteins were assayed for the ability to bind
radiolabeled TR DNA as previously described (Ballestas
and Kaye, 2001). Briefly, 10  106 BJAB cells were
transfected in 400 Al at 200 V, 960 AF in a 0.4-cm gap
cuvette using a Biorad Electroporator with 20 Ag of F-
LANA1, F-LANA1 779–1049, F-LANA1 779–1162, or F-
LANA1 981–1162. After 48 h, cells were lysed in lysis
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 2
mM EDTA, 25 mg/ml aprotinin, 25 mg/ml leupeptin, 1 mM
PMSF). Cell lysates were incubated with M2 anti-FLAG
monoclonal antibody conjugated beads (Sigma) or isotype-
matched control antibody bound to protein G beads. West-
ern blotting detected F-LANA1, F-LANA1 779–1049, F-
LANA1 779–1162, or F-LANA1 981–1162 only in M2
immune precipitates. The TR probe (50000 cpm) was
incubated with the beads in binding buffer (Ballestas and
Kaye, 2001). Alternatively, GST or GST LANA1 982–1162
(10 Ag) bound to glutathione beads was incubated with
50000 cpm of TR probe under similar conditions (Ballestas
and Kaye, 2001; Smith and Johnson, 1988). Bound DNA
was eluted off the beads by boiling for 5 min in SDS buffer
and resolved in a non-denaturing 5% polyacrylamide gel.
Signal was detected by autoradiography.
Co-immunoprecipitation
COS cells (5  106) were cotransfected by electropora-
tion with 15 Ag of pcDNA3 myc-LANA1 and 15 Ag of a
FLAG-tagged LANA1 mutant. Approximately 48 h after
transfection, cells were lysed in lysis buffer (50 mM N-2-
hydroxyethylpiperazine-NV-2-ethanesulfonic acid (HEPES,
pH 7.2), 250 mM NaCl, 2 mM EDTA, 1 mM phenyl-
methylsulfonyl fluoride (PMSF), 1% NP-40, 10% glycerol,
and protease inhibitors (Roche)). Lysates were precleared
with protein G-Sepharose beads (Gibco, BRL), incubated
overnight with mouse anti-myc monoclonal antibody
(9E10), and immune complexes precipitated. Beads were
washed five times with lysis buffer, and eluted by boiling in
SDS-PAGE sample buffer. Proteins were resolved by 8%
SDS-PAGE. Immune precipitations of myc-LANA1 were
confirmed by anti-myc immunoblot.
TR DNA replication assay
BJAB cells (10  106) were cotransfected with 30 Ag of
Z6-BE (Ballestas and Kaye, 2001) and 40 Ag of pSG5
vector, F-LANA1, F-LANA1 D1007–1021, or F-LANA1
1058VI1059!AA. Forty-eight hours after transfection, cells
were incubated at 37jC for 1 h in Hirt (Hirt, 1967)
extraction buffer (0.6% SDS, 10 mM Tris–HCl, pH 7.5,
T. Komatsu et al. / Virology 319 (2004) 225–236 23510 mM EDTA). High molecular weight DNA was precip-
itated by addition of 1 M NaCl and incubation at 4jC
overnight. Lysates were clarified by centrifugation at 12000
 g, supernatants phenol–chloroform extracted, and DNA
precipitated. Extracted DNA (10 Ag) was digested with NheI
and DpnI, resolved in a 0.7% agarose gel, transferred to a
nylon membrane, and DNA detected with the TR probe.
The TR probe was 32P radiolabeled by random priming of a
0.8 kb TR DNA fragment. Expression of F-LANA1, F-
LANA1 D1007–1021, and F-LANA1 1058VI1059!AA
were confirmed by immunoblot.
Selection of G418 resistant cells, Gardella gel analysis, and
immunofluorescent microscopy
Hygromycin (200 U/ml) (Calbiochem)-resistant BJAB
(KSHV uninfected) B lymphoblastoid cells stably express-
ing F-LANA1 D1007–1021 or F-LANA1 1058VI1059!AA
were generated (Ballestas et al., 1999) and then electro-
porated with Z6-BE and selected for G418 resistance (600
Ag/ml) (Gibco). Episomal DNA was resolved in Gardella
(Gardella et al., 1984) gels, DNA transferred to nylon
membranes, and detected with 32P-labeled TR probe (Bal-
lestas et al., 1999; Ballestas and Kaye, 2001). Immunoflu-
orescent microscopy was performed as described previously
(Ballestas et al., 1999).Acknowledgments
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